Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

摘要: LBA3506 Background: In patients (pts) with KRAS, wild-type metastatic colorectal cancer (mCRC) a head to comparison of anti-EGFR- and anti-VEGF-directed first-line therapy has not been reported regard the FOLFIRI backbone. The AIO KRK-0306 study was therefore designed as randomized multicenter trial compare efficacy plus cetuximab bevacizumab in mCRC pts pretreated for disease. Methods: Pts were (Tournigand regimen) every two wks (400 mg/m² day 1, followed by 250 wkly = arm A) or (5 mg/kg B). intent-to-treat (ITT) population comprised all who had at least completed one application therapy. While recruitment initially independent KRAS status, an amendment confined inclusion wildtype (WT) tumors. Recruitment October 2012. primary endpoint objective response rate (ORR, investigators read). Results: Among 735 ...